Salvador Rico, MD, PhD, on Developing Gene Regulation Therapy for Dravet Syndrome

Commentary
Video

The chief medical officer of Encoded Therapeutics overviews the company’s timeline and strategy for its gene regulation program for Dravet syndrome.

"What our team did is they develop an engineered transcription factor that upregulates the expression of the healthy allele in patients who have Dravet syndrome. And one important characteristic is that it's... not only gene selective, but cell selective. And we're targeting expression of these transgene in GABAergic inhibitory interneurons, because there's a whole body of literature indicating the importance of the cells in the pathophysiology of the disease. So, this is a precision medicine approach that is targeted to reestablish that balance between inhibition and excitation.”

Encoded Therapeutics is continuing to develop and evaluate its lead gene regulation therapy, ETX-101, for the potential treatment of people with SCN1A -positive Dravet syndrome. The company announced in February that it had secured clearance for clinical trials evaluating ETX-101 in this population in the United States, United Kingdom, and Australia.1,2

CGTLive® spoke with Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, to learn more about ETX-101 and what differentiates it from other novel genetic therapies in the investigational field. He shared that the company should soon be initiatingthe clinical trials. He also gave an overview of the company’s strategy with its Dravet program, including the clinical trials, sharing data from natural history studies that Encoded has conducted, and connecting with patient advocacy groups to better understand what endpoints represent clinically meaningful changes for patients with Dravet and better inform clinical trial design.

REFERENCES
1. Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101. News release. Encoded Therapeutics. February 26, 2024. https://encoded.com/press-releases/encoded-therapeutics-announces-uk-cta-approval-for-dravet-syndrome-gene-therapy-candidate-etx101/
2. Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101. News release. Encoded Therapeutics. February 6, 2024. https://encoded.com/press-releases/encoded-therapeutics-announces-us-ind-clearance-and-australian-cta-approval-for-dravet-syndrome-gene-therapy-candidate-etx101/
Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Related Content
© 2025 MJH Life Sciences

All rights reserved.